We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Sceptics may question the robustness of an early glimpse of mid-stage data for a well-worn neurodegenerative disease candidate but it is tough to doubt how real the upside has been for Annovis Bio.